We were rejected by Celgene even though we were retired with no income source.
Bernstein wrote that Celgene is "doing the obvious" but concedes the strategy makes sense.
"The rationale for the deal is fairly clear, " says Sol Barer, chief executive of Celgene .
Year-to-date, Gilead is ahead 31 percent, Celgene 50 percent and Biogen easily a snappy 35 percent.
According to Celgene's market research, 15% of MDS patients are treated with either Revlimid or Vidaza.
When it was a loss-making company, Celgene was one of the early beneficiaries of this program.
FORBES: Billion Dollar Policy Ideas for Supporting Biotech Innovation
Barer says Celgene is open to applying for approval one disease at a time.
It was revived by Celgene and approved in 1998 as a treatment for leprosy.
That means, among other things, that Celgene can't market the drug for its main use.
Celgene (nasdaq: CELG - news - people ), there's a dissimilar quandary.
But by 1990 Celgene was still unprofitable and had nowhere near the margins its clients enjoyed.
Currently, Celgene is enrolling patients for a phase III trial in MDS, List says.
In other words, this could help everyone from tiny biotechs like Exelixis to giants like Celgene.
Celgene acts OK and biotech houses like Genzyme, for example, aren't priced out of reach.
Analysts called the deal sensible but warned that it might hurt Celgene shares in the short term.
The study is a victory for Celgene (nasdaq: CELG - news - people ).
Celgene has already submitted an application to the FDA to approve the drug for multiple myeloma as well.
The few health care properties that sell at premiums are mid-teens growers like Celgene, Gilead, Express Scripts and Medco.
Robert Hariri, corporate co-chair and CEO of Celgene Cellular Therapeutics, welcomed the crowd.
Researchers at the Dana-Farber Cancer Institute in Boston took Celgene's improved version, Revlimid, and rushed it into myeloma trials.
But just because she played a key role in Thalomid's development doesn't prove that Celgene owes her a dime.
There is no doubt Jacobson played a pivotal role in developing Celgene's drugs.
The market still starved for growth stories wants Biogen, Gilead Sciences and Celgene.
We'd like to highlight four companies with unique approaches to stem cell therapies: Cytori Therapeutics, Geron, Athersys and Celgene.
Over the next eight years Celgene quadrupled the price of thalidomide, bringing it in line with other effective cancer pills.
Investors who have bid Celgene's stock up to 76 times 2006 earnings believe that the company will overcome this criticism.
Celgene scientists still don't know exactly how thalidomide works, only that it is extremely effective at stopping the malignant cells.
For instance, most use of Celgene 's (nadsaq: CELG - news - people ) Thalomid is off-label.
Within the next six months Celgene will likely win approval to market both Thalomid and Revlimid as treatments for multiple myeloma.
Last week Celgene described its stem cell program research and development in a central setting for the analytical and research community.
应用推荐